APOL1 kidney disease is a life threatening, genetically driven condition that is estimated to impact close to one million people of West African ancestry in the U.S. alone.
Maze scientists analyzed a new APOL1 genetic variant, now known as N264K, that protects people with the G1 and G2 risk variants. Through our research, we have established a better understanding APOL1’s role in kidney disease and how we might intervene with a new product candidate, MZE829, specifically designed to copy the effects of the N264K protective variant.
